Friday, January 30, 2026

North Korea Tests New Surface-to-Air Missiles, Claims Cruise Missile Interception Capability

North Korea tests new surface-to-air missiles, possibly a clone of the Russian Tor system, showing improved interception capabilities.

NewJeans Breaks Silence: Inside the Drama with HYBE and Min Hee Jin!

K-pop girl group NewJeans stirred controversy by directly addressing their conflict with HYBE and Min Hee Jin, a director at ADOR. 

People Power Party Denounces Decision To Shift Military Demarcation Line Standards As Security Self-Harm Amid Submissive Lee Government Policy

The People Power Party condemned the Joint Chiefs of Staff for altering MDL criteria, claiming it compromises national security.

Tag: Eli Lilly

North KoreaKoreaKimMilitarySouth KoreaAImarketrelationsInternational

Eli Lilly vs. Novo Nordisk: A $1.2 Billion Bet Reveals Two Very Different Futures for Obesity Drugs

Eli Lilly and Novo Nordisk are pursuing different strategies in the obesity treatment market, focusing on expansion versus core strengths.

Nvidia and Eli Lilly: How AI is Revolutionizing Drug Development in 2026

Nvidia partners with Eli Lilly to enhance AI in drug development, aiming to revolutionize the biotech industry.

Rising Use of GLP-1 Drugs May Be Linked to Rare Pancreatitis Cases, Study Finds

Reports of acute pancreatitis linked to GLP-1 diabetes drugs surge in the UK, prompting investigations and conflicting academic findings.

Ozempic Maker Swaps CEO, Bets $2.2B on New Obesity Drug Fight

Novo Nordisk's leadership change aims to reclaim its obesity treatment market share amid competition from Eli Lilly's Mounjaro.

New Study: Mounjaro Helps Users Drop Over 50 Pounds

Eli Lilly's Mounjaro leads U.S. obesity drug market, outperforming semaglutide in weight loss efficacy and safety.

Novo Nordisk Pushes for First Oral Obesity Drug Approval

Novo Nordisk seeks FDA approval for oral Wegovy, potentially the first oral obesity treatment, amid competition with Eli Lilly.

Eli Lilly’s Oral GLP-1 Shows 7.9% Weight Loss in Type 2 Diabetes Trial

Eli Lilly's orforglipron shows promise in Phase 3 trials for diabetes and obesity, offering an oral alternative to injectables.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.